Advertisement

Table of contents

  1. Thomas Zander, Valentin Goede, Michael Hallek
  2. Daniel H. Schanne, Anca-L. Grosu, Dan G. Duda
  3. Ulrich Hacker, Florian Lordick
  4. Martha M. Kirstein, Arndt Vogel
  5. Herbert Rübben, Andrej Panic
  6. Thilo Hackert, Laura Wüsten, Markus W. Büchler
  7. Jin-Sung Park, Intae Park, Gou Young Koh
  8. Weibin Hou, Stefan Duensing
  9. Andreas Pircher, Normann Steiner, Eberhard Gunsilius
  10. Gordon Jayson, James O’Connor
  11. Charlotte Benson, Michela Libertini
  12. Massimo Di Maio, Silvia Novello, Enrica Capelletto, Giorgio Vittorio Scagliotti
  13. Roser Pons-Cursach, Oriol Casanovas
  14. Iratxe Zuazo-Gaztelu, Oriol Casanovas
  15. Peter Bronsert, Martin Werner
  16. Lakshmi Venkatraman, Lena Claesson-Welsh
  17. Gerald Bastian Schulz, Alexander Karl
  18. Thalia Erbes, Juliane Farthmann, Kai Berner
  19. Thomas Moehler, Dirk Hose, Mindaugas Andrulis, Anja Seckinger, Hartmut Goldschmidt
  20. Krisztian Homicsko, Dominik Berthold
  21. Malgorzata Banys-Paluchowski, Tanja Fehm, Volkmar Müller

About this book

Introduction

Understanding of the molecular mechanisms of tumor development has increased considerably in recent years. As a consequence, the development of targeted therapies has proceeded rapidly, contributing to new drugs against cancer which are now under clinical investigation. Among these new therapies, anti-angiogenic drugs are of particular importance because they can be used against many different types of cancer. This is due to the fact that tumor angiogenesis seems to be involved in most if not all solid metastasizing malignancies.   The first part of this book summarizes the knowledge acquired on the molecular entities that play a role in tumor angiogenesis and their mechanisms of action. Furthermore, the identification of molecular markers and their validation as predictive and/or prognostic tools is reviewed. In the second and most important part, the clinical applications of anti-angiogenic treatments are documented for a wide variety of tumors. In particular, the modes of combination with other targeted and/or cytotoxic cancer therapies are presented.​

Keywords

Biomarkers Oncology Personalised Tumor Therapy Targeted Tumor Therapy Tumor-Angiogenesis

Editors and affiliations

  • Dieter Marmé
    • 1
  1. 1.Tumor Biology CenterFreiburgGermany

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-31215-6
  • Copyright Information Springer Nature Switzerland AG 2019
  • Publisher Name Springer, Cham
  • eBook Packages Medicine
  • Online ISBN 978-3-319-31215-6
Industry Sectors
Pharma
Health & Hospitals
Biotechnology